Avitar (CE) (USOTC:AVTI)
Historical Stock Chart
From Jul 2019 to Jul 2024
CANTON, Mass., Feb. 14 /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC:AVTI.OB) (BULLETIN BOARD: AVTI.OB) has released financial results for the three months ended December 31, 2006.
For the quarter ended December 31, 2006, Avitar's revenues from continuing operations increased to $1,045,000 from $907,000 in the quarter ended December 31, 2005.
The net loss was $943,000, or $0.08 per share, for the quarter ended December 31, 2006 compared with a net loss of $892,000, or $0.23 per share for the quarter ended December 31, 2005. The net loss for the three months ended December 31, 2006 reflects a decrease in income from discontinued operations of $120,000, an increase in interest and financing expenses of $97,000 and a decrease in non-cash income of approximately $22,000 resulting from changes in fair market value of derivative securities and warrants, offset in part by increases in revenue of approximately $138,000 and decreases in operating expenses of approximately $50,000.
"Our technology and its associated value proposition for workplace drug testing, continues to be received well in the marketplace," said Peter P. Phildius, Chairman and CEO. "Our viral marketing strategy, particularly our various web-based communication techniques, have positioned us to be regarded as the thought leaders in workplace oral fluid drug testing. We will continue to exploit this high-return and cost effective approach in the months ahead."
About Avitar, Inc.
Avitar, Inc. develops, manufactures, and markets innovative and proprietary products. Their products span the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB(TM), an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in- vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at http://www.avitarinc.com/.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including financing risks and the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Contact:
Jay C. Leatherman The Investor Relations Group
Avitar Inc. Investors:
781-821-2440 Erika Moran/Tom Caden,
212-825-3210
http://www.avitarinc.com/
Media:
Bill Douglass, 212-825-3210
CHART FOLLOWS
Avitar, Inc.
Summary of Financial Results
(in thousands, except per share amounts)
Quarter Ended December 31,
2006 2005
Sales $1,045 $907
Operating Expenses:
Cost of Sales 749 659
Selling, General and Administrative 936 1,038
Research and Development 92 130
Total Operating Expenses 1,777 1,827
Operating Loss (732) (920)
Other Expenses (211) (92)
Loss from Continuing Operations (943) (1,012)
Discontinued Operations:
Income from the Disposal of USDTL - 120
Loss from Discontinued Operations - 120
Net Loss $(943) $(892)
Basic and Diluted Loss Per Share
From Continuing Operations Before
Discontinued Operations $(0.08) $(0.26)
Basic and Diluted Net Loss Per Share $(0.08) $(0.23)
Weighted Average Number of Shares and
Common Equivalent Shares Outstanding 11,667,963 4,045,403
Selected Balance Sheet Items:
12/31/2006
Cash $205
Total Assets 2,056
Total Liabilities 7,853
Convertible and Redeemable
and Convertible Preferred Stock 3,185
Stockholders' Deficit (8,981)
DATASOURCE: Avitar, Inc.
CONTACT: Jay C. Leatherman of Avitar Inc., +1-781-821-2440, or
; or Investors, Erika Moran,
, or Tom Caden,
, both of The Investor Relations Group for
Avitar, Inc., +1-212-825-3210; or Media, Bill Douglass of The Investor
Relations Group, +1-212-825-3210, or